Most of our competitors rely on their own knowledge. So do we. With an added extra: we are involved in “The Biosimilars Group” expert network and have worked with other biosimilar experts to design a process for the development of biosimilar products. It takes into account the basic biosimilar concept, i.e. a drug’s high degree of similarity with drugs already on the market, from the initial development step to final production. We implement this knowledge rigorously, thus securing time- and cost advantages.
Celonic develops efficient cell lines. So efficient, in fact, that production costs are considerably lower than for standard production cell lines. Celonic therefore gives its clients a head start in the highly competitive biosimilars market. You can benefit from excellent positioning in the market right now.